Shares of SAGE Therapeutics Inc (NASDAQ:SAGE) have been given an average rating of “Buy” by the sixteen analysts that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $175.75.
Several brokerages have recently weighed in on SAGE. BidaskClub cut SAGE Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. BMO Capital Markets reiterated an “outperform” rating and issued a $112.00 price target (up from $85.67) on shares of SAGE Therapeutics in a research report on Friday, November 17th. Needham & Company LLC lifted their price target on SAGE Therapeutics from $100.00 to $193.00 and gave the company a “buy” rating in a research report on Thursday, December 7th. Raymond James Financial lifted their price target on SAGE Therapeutics to $109.00 and gave the company a “buy” rating in a research report on Thursday, November 9th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $198.00 price target on shares of SAGE Therapeutics in a research report on Friday, December 8th.
In related news, insider Stephen Kanes sold 44,000 shares of the business’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $177.18, for a total transaction of $7,795,920.00. Following the completion of the transaction, the insider now directly owns 46,348 shares in the company, valued at $8,211,938.64. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Jeffrey M. Jonas sold 210,247 shares of the business’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $157.45, for a total value of $33,103,390.15. Following the transaction, the chief executive officer now owns 211,473 shares of the company’s stock, valued at $33,296,423.85. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 314,247 shares of company stock valued at $50,465,110. 6.10% of the stock is owned by company insiders.
Shares of SAGE Therapeutics (NASDAQ SAGE) traded down $0.53 during midday trading on Tuesday, hitting $163.60. The stock had a trading volume of 649,100 shares, compared to its average volume of 658,175. The stock has a market capitalization of $6,580.00, a PE ratio of -23.33 and a beta of 2.97. SAGE Therapeutics has a one year low of $59.50 and a one year high of $195.97.
TRADEMARK VIOLATION WARNING: This news story was originally posted by BBNS and is the property of of BBNS. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://baseballnewssource.com/markets/sage-therapeutics-inc-sage-receives-175-75-consensus-target-price-from-brokerages/1886609.html.
About SAGE Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.